BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15641217)

  • 1. The role of free to total prostate-specific antigen ratio for prostate cancer in screening patients with total serum levels between 4 and 20 ng/ml.
    Wu CT; Chuang CK; Chou CC; Chu SH; Chen HW; Chen CS; Chiang YJ; Liao SK
    Chang Gung Med J; 2000 Mar; 23(3):142-8. PubMed ID: 15641217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cutoff level of free/total prostate specific antigen (f/t PSA) ratios in the diagnosis of prostate cancer: a validation study on a Turkish patient population in different age categories.
    Erol B; Gulpinar MT; Bozdogan G; Ozkanli S; Onem K; Mungan G; Bektas S; Tokgoz H; Akduman B; Mungan A
    Kaohsiung J Med Sci; 2014 Nov; 30(11):545-50. PubMed ID: 25458043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
    Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
    Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of the relative probability for prostate cancer to avoid unnecessary biopsy.
    Okamura K; Takaba H; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Nagasaka T
    Int J Urol; 2005 Apr; 12(4):346-52. PubMed ID: 15948720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proper cut-off value of free to total PSA ratio for detection of prostate cancer in Korean men.
    Im YJ; Kim JW; Hong SJ; Chung BH
    Yonsei Med J; 2004 Oct; 45(5):873-8. PubMed ID: 15515198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostate cancer].
    de La Taille A; Houlgatte A; Houdelette P; Berlizot P; Fournier R; Ricordel I
    Prog Urol; 1997 Jun; 7(3):455-63. PubMed ID: 9273075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of the (F/T)/PSA density ratio to detect prostate cancer.
    Veneziano S; Pavlica P; Compagnone G; Martorana G
    Urol Int; 2005; 74(1):13-8. PubMed ID: 15711102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
    Nakano Y; Okamura K; Takamura S; Okamoto N; Narishima M; Yoshino Y; Hattori R; Ono Y; Ohshima S; Nagasaka T
    Int J Urol; 2005 Aug; 12(8):721-7. PubMed ID: 16174045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Values for free/total prostate-specific antigen ratio as a function of age: necessity of reference validation in a Turkish population.
    Mungan AG; Erol B; Akduman B; Bozdogan G; Kiran S; Yesilli C; Mungan NA
    Clin Chem Lab Med; 2007; 45(7):912-6. PubMed ID: 17617037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer detection by prostate-specific antigen-related parameters.
    Segawa N; Gohji K; Iwamoto Y; Ueda H; Katsuoka Y
    Hinyokika Kiyo; 2003 Jul; 49(7):405-10. PubMed ID: 12968483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of free prostate specific antigen serum level and its related parameters in the diagnosis of prostate cancer.
    Haroun AA; Hadidy AS; Awwad ZM; Nimri CF; Mahafza WS; Tarawneh ES
    Saudi J Kidney Dis Transpl; 2011 Mar; 22(2):291-7. PubMed ID: 21422628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
    Catalona WJ; Smith DS; Wolfert RL; Wang TJ; Rittenhouse HG; Ratliff TL; Nadler RB
    JAMA; 1995 Oct; 274(15):1214-20. PubMed ID: 7563511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The usefulness of percentage of free prostate specific antigen/prostate specific antigen density in the diagnosis of prostate cancer].
    Han G; Gao JP; Cao XL; Hong BF; Tang J
    Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):379-81. PubMed ID: 16638346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma.
    Thakur V; Singh PP; Talwar M; Mukherjee U
    Dis Markers; 2003-2004; 19(6):287-92. PubMed ID: 15258330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary/serum prostate-specific antigen ratio: comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection.
    Irani J; Salomon L; Soulié M; Zlotta A; de la Taille A; Doré B; Millet C
    Urology; 2005 Mar; 65(3):533-7. PubMed ID: 15780371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening.
    Reissigl A; Klocker H; Pointner J; Fink K; Horninger W; Ennemoser O; Strasser H; Colleselli K; Höltl L; Bartsch G
    Urology; 1996 Dec; 48(6A Suppl):62-6. PubMed ID: 8973702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do changes in a high serum prostate-specific antigen level and the free/total prostate-specific antigen ratio after antibiotic treatment rule out biopsy and the suspicion of cancer?
    Dirim A; Tekin MI; Koyluoglu E; Oguzulgen AI; Peskircioglu L; Ozkardes H
    Urol Int; 2009; 82(3):266-9. PubMed ID: 19440011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.